MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

Maturities of marketablesecurities$29,000K Proceeds from sale ofmarketable securities$26,342K Proceeds from term loan$15,000K Proceeds from theexercise of stock options$25K Net cash provided byinvesting activities$55,024K Net cash provided byfinancing activities$14,862K Canceled cashflow$318K Canceled cashflow$163K Increase (decrease) incash and cash...$39,995K Canceled cashflow$29,891K Purchases of property andequipment$318K Stock-based compensationexpense$1,193K Non-cash operating leaseexpense$109K Depreciation$63K Amortization of debt discountand deferred...$5K Payments of issuancecosts associated with...$163K Net cash used inoperating activities-$29,891K Canceled cashflow$1,370K Net loss-$26,869K Accrued liabilities-$2,464K Accounts payable-$1,113K Prepaid expenses andother current assets$508K Amortization and accretion ofpremiums/discounts on marketable...$237K Operating lease liability-$70K
Cash Flow

Avalyn Pharma Inc. (AVLN)

Avalyn Pharma Inc. (AVLN)

source: myfinsight.com